Peptides for Weight Loss

Summary: Only three peptide drugs are FDA-approved for weight loss in 2026: semaglutide, tirzepatide, and liraglutide. Everything else is either in trials or sold by gray-market suppliers with little to no human data.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short version: only three peptide drugs are FDA-approved for weight loss in the United States, and all three are GLP-1 receptor agonists. Semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda). Everything else marketed as a "weight loss peptide" is either in clinical trials, sold off-label, or pushed by gray-market suppliers on the strength of cell-line studies and Reddit posts. The gap in evidence between those two groups is enormous.

This page sorts them honestly. What is approved, what works in trials, and what is being sold with almost no human data behind it.

What "peptide" actually means here

A peptide is a short chain of amino acids. Insulin is a peptide. Oxytocin is a peptide. Wegovy is a peptide. The word does not imply natural, safe, or effective. It is a chemistry classification, not a marketing badge.

When the wellness industry says "peptides for weight loss," it usually means one of two very different things:

• A prescription GLP-1 drug like semaglutide or tirzepatide, with Phase 3 trial data and FDA approval.
• A research compound (AOD-9604, MOTS-c, BPC-157, tesamorelin, 5-Amino-1MQ, CJC-1295) sold without a prescription by suppliers labeling vials "for research use only."

Both are peptides. One has years of head-to-head trials against placebo, the other does not. Treating them as comparable products is the central marketing trick of the gray-market peptide industry.

FDA-approved peptides for weight loss

These are the only three peptide drugs the FDA has approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. All are subcutaneous injections, with one exception: oral semaglutide tablets, approved for obesity in late 2025.

Semaglutide (Wegovy, Ozempic)

Semaglutide started the modern GLP-1 era. The STEP-1 trial published in NEJM in 2021 reported a mean body weight reduction of 14.9% over 68 weeks at the 2.4 mg weekly dose, compared with 2.4% on placebo ^[1]. About 86% of participants lost at least 5% of their starting weight. Wegovy is the obesity-indication brand. Ozempic is the same molecule at lower doses, FDA-approved for type 2 diabetes only, but widely prescribed off-label for weight loss.

A higher-dose formulation called Wegovy 7.2 mg landed in 2025 with roughly 19% mean weight loss at 72 weeks in trials. An oral semaglutide tablet for obesity was approved the same year, dosed at 25 mg daily with around 14% weight loss at 64 weeks. The injectable version remains the workhorse.

Tirzepatide (Zepbound, Mounjaro)

Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor. In SURMOUNT-1, the 15 mg weekly dose produced 22.5% average body weight loss over 72 weeks, with 36.2% of participants losing 25% or more ^[2]. The dual mechanism appears to deliver more weight loss than GLP-1 alone, and many patients report better tolerability than semaglutide at equivalent efficacy. Zepbound is the obesity brand. Mounjaro is the diabetes brand, identical molecule.

SURMOUNT-4 added a durability finding that matters clinically. Patients kept on tirzepatide past 36 weeks lost an additional 5.5% body weight, while those switched to placebo regained roughly 14% within a year. The pattern repeats across the GLP-1 class. Stopping the drug reverses most of the loss. Obesity is now treated as a chronic condition that needs chronic medication.

Liraglutide (Saxenda)

Saxenda was the first GLP-1 approved specifically for chronic weight management, in 2014. It produces about 8% mean body weight loss at 56 weeks at the 3 mg daily dose ^[5]. The catch is dosing. Liraglutide has a short half-life and requires a daily injection, where semaglutide and tirzepatide work weekly. The weight loss numbers are also roughly half what tirzepatide delivers. Saxenda still has a place, particularly when newer GLP-1s are unavailable, but it is no longer the first choice.

Investigational peptides with serious data

These are not yet FDA-approved but have human trial data strong enough to take seriously. Expect at least one of them on the market by 2027 or 2028.

Retatrutide

A triple agonist hitting GLP-1, GIP, and the glucagon receptor. The glucagon arm pushes up energy expenditure on top of the appetite suppression. In a Phase 2 trial published in NEJM in 2023, the 12 mg weekly dose produced 24.2% mean body weight loss over 48 weeks ^[3]. That approaches the territory of bariatric surgery (typically 25 to 30%) with a weekly injection. Phase 3 (TRIUMPH program) is reading out through 2026. Retatrutide is the leading candidate for the highest-efficacy weight loss drug ever brought to market.

Survodutide

A dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim. Phase 2 data published in 2024 showed about 18.7% mean weight loss at 46 weeks at the highest dose. Phase 3 trials in obesity and MASH (metabolic dysfunction-associated steatohepatitis) are in progress. Survodutide is interesting because the glucagon receptor activation appears to clear liver fat aggressively, which is a separate clinical win on top of the weight number.

CagriSema (cagrilintide + semaglutide)

Cagrilintide is a long-acting amylin analog. By itself it produces modest weight loss. Combined with semaglutide in a single weekly injection, it produced 22.7% weight loss at 68 weeks in Phase 3, putting it in tirzepatide's range. Novo Nordisk filed for approval in 2025; expect a launch decision in 2026.

Oral GLP-1s and next-generation candidates

Several non-peptide oral small molecules that hit the GLP-1 receptor (orforglipron, danuglipron, MK-6024) are deep in Phase 3 trials. They are not technically peptides because they are not made of amino acids, but they target the same receptor and are likely to compete directly with semaglutide and tirzepatide on convenience and price once approved.

The gray market: peptides sold without prescriptions

This is where the marketing gets aggressive and the data gets thin. The compounds below are sold by online suppliers as "research chemicals," with labels that say "not for human consumption." That disclaimer is legal cover, not a reflection of how the products are actually used. Some have small human trials. Most do not. None are FDA-approved for weight loss, and a few have no credible weight loss data at all.

AOD-9604

A 16-amino-acid fragment of human growth hormone, marketed since the early 2000s as a fat-burner. The original phase 2 trial in obese adults, sponsored by Metabolic Pharmaceuticals, ran for 24 weeks at 1 mg daily and found no statistically significant difference in body weight versus placebo. That trial result has been quietly downplayed by suppliers ever since. AOD-9604 continues to sell on the strength of in vitro lipolysis data and testimonials.

5-Amino-1MQ

An oral small molecule (not actually a peptide, despite the marketing) that inhibits the enzyme NNMT, which is involved in fat storage in white adipose tissue. Animal data is genuinely interesting. Human data is essentially zero. Sold orally at 50 to 150 mg per day. Treat as experimental, not as a weight loss tool with proof behind it.

BPC-157

A 15-amino-acid synthetic peptide derived from a stomach protein. Marketed mostly for tendon and gut healing. Has no clinical trial data supporting weight loss. The fact that suppliers sometimes include it in "weight loss stacks" is a marketing decision, not an evidence-based one.

MOTS-c

A mitochondrial-derived peptide that activates AMPK, the same metabolic switch triggered by exercise. Preclinical data in mice is striking. Human data exists in tiny pilot studies on insulin sensitivity. No properly powered weight loss trial has been completed. Sold subcutaneously at 5 to 10 mg per week.

Tesamorelin

The most legitimate of the gray-market crowd. Tesamorelin is actually FDA-approved, but for a narrow indication: reducing excess abdominal fat in HIV-associated lipodystrophy, sold as Egrifta. It is a growth hormone releasing hormone analog. Outside that specific population it has not been studied for general obesity. The visceral fat reduction in the approved population is real (about 18% over 26 weeks), but generalizing that to non-HIV adults is an extrapolation, not data.

CJC-1295 and Ipamorelin

Growth hormone secretagogues stacked together to boost endogenous GH. Marketed for body recomposition rather than scale weight. The mechanism is real. The human trial data specifically for weight loss is not. Body composition changes accumulate over months and are modest compared with anything in the GLP-1 class.

What about peptide pills for weight loss?

Three categories ship as oral capsules, and only one of them has real data.

• Oral semaglutide (Wegovy tablet). FDA-approved in late 2025 for obesity at 25 mg daily. About 14% mean weight loss at 64 weeks. This is the only legitimate peptide pill for weight loss on the market.
• 5-Amino-1MQ capsules. Oral, but not a peptide, and human evidence is essentially absent.
• "Collagen peptide" weight loss supplements. Collagen peptides are hydrolyzed protein fragments sold as a powder or pill. There is no credible evidence they cause weight loss. Some small trials show they improve skin elasticity and joint comfort. None show body weight reduction beyond the small effect of any added dietary protein. Collagen peptides do not act on GLP-1, GIP, or glucagon receptors. They will not suppress appetite the way GLP-1 drugs do.

The marketing conflation of "collagen peptides" with "peptides for weight loss" is a search engine accident, not a clinical reality. If your goal is weight loss, collagen does not help. If your goal is more dietary protein for satiety, any protein source works.

Are peptides safe for weight loss?

For the FDA-approved GLP-1s, the safety profile is well characterized. The common side effects are nausea, vomiting, constipation, and diarrhea, mostly during dose escalation. Serious but rare risks include pancreatitis, gallbladder disease, and an FDA boxed warning about medullary thyroid carcinoma based on rodent data (no human signal has been confirmed). Hypoglycemia risk rises when GLP-1s are combined with insulin or sulfonylureas. Years of post-marketing surveillance covering millions of patients have not surfaced surprises beyond what the trial data predicted.

For gray-market peptides, the honest answer is that no one knows. There are no large safety databases for AOD-9604, BPC-157, MOTS-c, or 5-Amino-1MQ in humans at the doses people self-administer. Short-term studies have not flagged dramatic toxicity, but absence of data is not evidence of safety. Long-term use is unstudied.

Rapamycin, off-topic but worth a sentence

Rapamycin is an mTOR inhibitor used for organ transplant immunosuppression and being studied for longevity. It is not a peptide. It is not approved or studied for weight loss. Small longevity protocols use it weekly at low doses. Any weight loss reported is anecdotal and not the reason to take it. Do not put it in the same conversation as semaglutide.

The honest ranking

If your question is "what works," the answer is short:

1. Tirzepatide if you can access it. Highest weight loss of any approved drug, weekly injection, well-tolerated.
2. Semaglutide if tirzepatide is unavailable or unaffordable. Long track record, weekly injection, slightly less weight loss.
3. Liraglutide if neither of the above works for you. Older, daily, lower efficacy, but still real.
4. Retatrutide, survodutide, CagriSema when approved. Pipeline candidates worth watching.
5. Everything else. Either no good human data, or human data that did not show benefit. Spend the money on a GLP-1 instead.

That ordering is uncomfortable for the gray-market peptide industry but it matches what the trials actually show. The mechanism of weight loss that has the most consistent, large-effect human data is GLP-1 receptor activation. Drugs that activate GLP-1 work. Drugs that do not, mostly do not.

Cost, access, and what "compounded" means

Brand-name semaglutide (Wegovy) lists around $1,350 per month. Tirzepatide (Zepbound) lists around $1,060 per month. Manufacturer cash programs (NovoCare for semaglutide, Lilly Direct for tirzepatide) bring those down to roughly $200 to $500 per month for self-pay patients, depending on dose and formulation.

Compounded GLP-1s from US compounding pharmacies became widespread during the 2024 and 2025 FDA shortage period and remain available through telehealth channels. Pricing typically runs $150 to $300 per month. Compounded products are not FDA-approved, are made from bulk powders, and quality varies between pharmacies. They are legal under 503A and 503B compounding rules in defined circumstances. They are not the same product as the brand-name version, even when the active ingredient is identical.

Research-grade peptides from overseas suppliers run cheaper still, often under $100 per month. They are not pharmaceutical grade and are not legal for human use.

Frequently asked questions

What are peptides for weight loss?

Short chains of amino acids that act on receptors involved in appetite, blood sugar, or metabolism. The three FDA-approved options are semaglutide, tirzepatide, and liraglutide, all GLP-1 receptor agonists.

What are the best peptides for weight loss?

Tirzepatide produces the highest average weight loss (about 22.5%) of any FDA-approved drug. Semaglutide is second (about 15%). Retatrutide may surpass both when approved.

Are peptide pills for weight loss real?

One is. Oral semaglutide (Wegovy 25 mg tablet) was FDA-approved in late 2025 and produces about 14% weight loss at 64 weeks. Most other oral peptide supplements have no credible weight loss data.

Are peptides safe for weight loss?

FDA-approved GLP-1s have a well-characterized safety profile with mostly GI side effects and rare serious events. Gray-market peptides have no comparable safety database in humans.

Do collagen peptides help with weight loss?

No. Collagen peptides are dietary protein fragments. They have no effect on appetite-regulating receptors and no trial evidence of causing weight loss beyond the modest effect of added protein.

What is survodutide and does it cause weight loss?

Survodutide is an investigational dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim. Phase 2 trials showed about 18.7% weight loss at 46 weeks. Phase 3 is ongoing.

What are the next generation weight loss drugs?

Retatrutide (triple agonist), survodutide (dual glucagon/GLP-1), CagriSema (cagrilintide plus semaglutide), and oral small-molecule GLP-1s like orforglipron. Most are expected to launch between 2026 and 2028.

Is rapamycin a peptide for weight loss?

No. Rapamycin is an mTOR inhibitor used for transplant immunosuppression and studied for longevity. It is not a peptide and has no weight loss indication or trial data.

Can I buy peptides for weight loss without a prescription?

FDA-approved peptides (semaglutide, tirzepatide, liraglutide) require a prescription. Research-grade peptides sold online without a prescription are not legal for human use and are not quality-controlled like pharmaceutical products.

Which peptide is closest to bariatric surgery results?

Retatrutide, with 24.2% mean weight loss in Phase 2. That approaches the 25 to 30% typical of sleeve gastrectomy, though it is not yet FDA-approved.

Bottom line

The phrase "peptides for weight loss" covers two very different markets. One is the FDA-approved GLP-1 class with rigorous trial data and known safety. The other is a gray market of research compounds with thin evidence and no quality control. The first works. The second mostly does not. If weight loss is the goal, see a clinician and discuss semaglutide, tirzepatide, or liraglutide. If a pipeline drug like retatrutide or survodutide reaches the market in the next year or two, the ranking will update. The basic logic will not: the peptides that work are the ones with Phase 3 data, and the ones with Phase 3 data are GLP-1 receptor agonists.